

Cornell chemists show ALS is a protein aggregation disease

23 October 2014, by Melissa Osgood

Using a technique that illuminates subtle changes in individual proteins, chemistry researchers at Cornell University have uncovered new insight into the underlying causes of Amyotrophic Lateral Sclerosis (ALS).

Brian Crane, professor of chemistry and chemical biology, led one study and co-authored a follow-up on a spectroscopic method that detects subtle changes to copper-containing proteins in solution. He and Jack Freed, professor of [physical chemistry](#), have developed the method together with Petr Borbat, associate director of Cornell's National Biomedical Center for Advanced ESR Technology.

The first study, which proved the principle of the technique – pulsed dipolar electron spin resonance (ESR) spectroscopy – was published Oct. 7 in *Biophysical Journal*; the second paper, which used the technique and others to connect ALS symptoms with protein aggregation was authored with collaborators from The Scripps Research Institute and appeared Oct. 14 in *Proceedings of the National Academy of Sciences (PNAS)*.

A complex neurodegenerative disease, ALS often has a genetic component – genetic defects that cause it can be inherited. Scientists have long known that one of the culprit genes codes for the protein "superoxide dismutase 1" or SOD1 – a critical copper-containing enzyme that protects cells against oxidative damage by destroying free radicals.

Scientists have surmised that ALS is a disease related to oxidative damage of neurons, and that might still be true, Crane said. But he and colleagues have provided strong evidence for another hypothesis: that SOD1 mutations cause ALS by destabilizing the SOD1 protein structure. This leads to increased motion of the proteins, which Crane likened to "breathing." This movement promotes their aggregation, or clumping together –

an event toxic to the healthy cell.

"ALS, in this form, appears to be a protein aggregation disease, much like Alzheimer's and Parkinson's diseases," Crane said.

For a long time, people have studied mutations in SOD1 to try to understand ALS, but the properties of normal proteins and mutated ones were found to be very similar. By using ESR spectroscopy, the scientists for the first time have seen definitive differences. By verifying with other methods, Crane said, the researchers showed that the dynamics of the proteins were dramatically changed by mutation, and that they showed a tendency to aggregate.

In the *PNAS* paper, X-ray scattering was also used to study structural changes and the ability of the proteins to interact with each other. The researchers found that levels of [protein](#) aggregation correlated with the severity of ALS symptoms.

Their conclusions point to the possibility of ALS being more linked to toxicity of aggregation and perhaps less about the effect of the mutations on SOD1 activity, Crane said. ALS is a late-onset disease, with people being affected in mid to late life. "Sporadic mutations in SOD1 arise from natural processes, but it's not really clear if they're actually going to generate the disease or not," he said.

Provided by Cornell University

APA citation: Cornell chemists show ALS is a protein aggregation disease (2014, October 23) retrieved 11 October 2022 from

<https://medicalxpress.com/news/2014-10-cornell-chemists-als-protein-aggregation.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.